Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States

Current Medical Research and Opinion

Volumn 27, Issue 8, 2011, Pages 1613-1622

  Schwartzberg, Lee ^a,b   Morrow, Gary ^c   Balu, Sanjeev ^d   Craver, Chris ^e   Gayle, Julie ^e   Cox, David ^d  

^a Accelerated Community Oncology Research Network   (United States)

^b WEST CLINIC   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d EISAI INC   (United States)

^e Premier Inc   (United States)

Author keywords

Antiemetic therapy; Cancer emesis; Hospital outpatient setting; Low emetogenic chemotherapy (LEC); Nausea; Vomiting

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; BUTYROPHENONE; CANNABINOID; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; LORAZEPAM; ONDANSETRON; PALONOSETRON; PHENOTHIAZINE; STEROID;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; FEMALE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; LOW EMETOGENIC CHEMOTHERAPY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOTION SICKNESS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEOPLASM; OUTPATIENT CARE; RETROSPECTIVE STUDY; UNITED STATES; URINARY TRACT CANCER; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUINUCLIDINES; SEROTONIN ANTAGONISTS; TIME FACTORS; VOMITING;

EID: 79960435777     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.596201     Document Type: Article

References (20)

1. Boer-Dennert M de, de Wit R, Schmitz PIM, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76:1055-61. (Pubitemid 27434663)
2. Glaus A, Knipping C, Morant R, et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004;12:708-15. (Pubitemid 39362649)
3. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2010. Available at: http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp [Last accessed 16 August 2010].
4. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47. (Pubitemid 46630595)
5. Fabi A, Barduagni M, Lauro S, et al. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 2003;11:156-61. (Pubitemid 36733809)
6. Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004;64:1125-32. (Pubitemid 38736896)
7. Aloxi injection (palonosetron hydrochloride) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc., 2009.
8. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer 2003;98: 2473-82. (Pubitemid 37466663)
9. Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatinbased chemotherapy: a doseranging clinical study. Ann Oncol 2004; 15:330-7. (Pubitemid 38262636)
10. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7. (Pubitemid 37304615)
11. Aapro MS, Grunberg SM, Manikhas GM, et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9. (Pubitemid 44400384)
12. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomised, comparative Phase III trial. Lancet Oncol 2009;10:115-24.
13. Weiner MG, Livshits A, Carozzoni C, et al. Derivation of malignancy status from ICD-9 codes. American Medical Informatics Association (AMIA) 2003 Symposium Proceedings: 1050.
14. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
15. Tonato M, Clark-Snow RA, Osoba D, et al. Emesis induced by low or minimal emetogenic risk chemotherapy. Support Care Cancer 2005;13:109-11. (Pubitemid 40558166)
16. Schwartzberg L, Szabo S, Gilmore J, et al. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderate or highly emetogenic chemotherapy (LEC/MEC/HEC). CMRO 2011;27:837-45.
17. Molassiotis A, Saunders MP, Valle J, et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008;16:201-8.
18. Pirri C, Katris P, Trotter J, et al. Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Canc 2010; Published online 3 September 2010.
19. Booth CM, Clemons M, Dranitsaris G, et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 2007;5:374-80. (Pubitemid 47559694)
20. Markman M. Progress in preventing chemotherapy-induced nausea and vomiting. Cleve Clin J Med 2002;69:609-17 (Pubitemid 34947056)